应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
06160 百济神州
已收盘 07-30 16:08:22
196.100
-3.000
-1.51%
最高
202.600
最低
193.300
成交量
359.30万
今开
201.600
昨收
199.100
日振幅
4.67%
总市值
3,022亿
流通市值
2,796亿
总股本
15.41亿
成交额
7.06亿
换手率
0.25%
流通股本
14.26亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
百济神州拟发行86.6万股新股 用于落实2018员工购股计划
财中社 · 18:41
百济神州拟发行86.6万股新股 用于落实2018员工购股计划
百济神州(06160)拟向全资子公司配发86.61万股新股以履行员购计划
公告速递 · 18:06
百济神州(06160)拟向全资子公司配发86.61万股新股以履行员购计划
百济神州(06160)根据股份计划发行86.61万股新股份
智通财经 · 18:02
百济神州(06160)根据股份计划发行86.61万股新股份
财报前瞻｜百济神州本季度营收预计增速稳健，机构观点偏正面
财报Agent · 07-29 23:58
财报前瞻｜百济神州本季度营收预计增速稳健，机构观点偏正面
异动解读｜百济神州盘中上涨3.33%，野村上调目标价至270.74港元提振情绪
行情直击 · 07-29 09:32
异动解读｜百济神州盘中上涨3.33%，野村上调目标价至270.74港元提振情绪
港股开盘向好 恒指高开0.7% 理想汽车-W（02015）涨4.47%
金吾财讯 · 07-29 09:25
港股开盘向好 恒指高开0.7% 理想汽车-W（02015）涨4.47%
【券商聚焦】国泰海通证券：全球多肽CDMO进入产能扩张周期
金吾财讯 · 07-29 09:21
【券商聚焦】国泰海通证券：全球多肽CDMO进入产能扩张周期
异动解读｜百济神州盘中下跌3.15%，生物科技板块集体回调
行情直击 · 07-28 14:34
异动解读｜百济神州盘中下跌3.15%，生物科技板块集体回调
【券商聚焦】交银国际：下半年医药板块有望迎来修复 但内部分化或持续加大
金吾财讯 · 07-28 10:01
【券商聚焦】交银国际：下半年医药板块有望迎来修复 但内部分化或持续加大
大行评级丨野村：上调百济神州目标价至270.74港元，预测次季经营利润同比增74%
格隆汇 · 07-27
大行评级丨野村：上调百济神州目标价至270.74港元，预测次季经营利润同比增74%
每日科创｜百济神州（688235）：25年首度盈利，稳居科创板市值最高药企
证券之星 · 07-27
每日科创｜百济神州（688235）：25年首度盈利，稳居科创板市值最高药企
百济神州(06160)涨3.92% 拟追加投资3亿美元扩建美国生产基地和临床研发中心
金吾财讯 · 07-24
百济神州(06160)涨3.92% 拟追加投资3亿美元扩建美国生产基地和临床研发中心
异动解读｜百济神州盘中上涨4.13%，追加3亿美元扩大美国生产布局
行情直击 · 07-24
异动解读｜百济神州盘中上涨4.13%，追加3亿美元扩大美国生产布局
百济神州/安进 FIC 双抗，皮下制剂进入 III 期
新浪医药 · 07-23
百济神州/安进 FIC 双抗，皮下制剂进入 III 期
百济神州追加3亿美元投资扩大美国生产布局
格隆汇 · 07-23
百济神州追加3亿美元投资扩大美国生产布局
百济神州汪来：公司的背水一战，研发做了这些事
第一财经 · 07-23
百济神州汪来：公司的背水一战，研发做了这些事
7月21日百济神州涨6.25%，创新药ETF银华基金重仓该股
证券之星 · 07-21
7月21日百济神州涨6.25%，创新药ETF银华基金重仓该股
百济神州涨6.25%，中邮证券二个月前给出“买入”评级
证券之星 · 07-21
百济神州涨6.25%，中邮证券二个月前给出“买入”评级
创新药板块活跃 荣昌生物(09995)涨7.28% 多支头部公募大举举牌港股创新药
金吾财讯 · 07-20
创新药板块活跃 荣昌生物(09995)涨7.28% 多支头部公募大举举牌港股创新药
异动解读｜百济神州盘中上涨3.39%，报192.5港元
行情直击 · 07-20
异动解读｜百济神州盘中上涨3.39%，报192.5港元
加载更多
公司概况
公司名称：
百济神州
所属市场：
SEHK
上市日期：
--
主营业务：
BeOne Medicines AG（原名：BeiGene Ltd）是一家全球肿瘤学公司，致力于为全球癌症患者研发新疗法。该公司产品组合涵盖血液学和实体瘤，致力于开发多样化的新型疗法。其产品包Brukinsa、Tevimbra和Pamiparib。Brukinsa是一种口服的布鲁顿酪氨酸激酶(BTK)小分子抑制剂。Tevimbra是一种人源化免疫球蛋白G4（IgG4）抗程序性细胞死亡蛋白1（PD-1）单克隆抗体，具有高亲和力和对PD-1的结合特异性。Tevimbra旨在最大限度地减少与巨噬细胞上Fc-γ（Fcy）受体的结合，帮助人体免疫细胞检测和对抗肿瘤。该公司正在开发的产品线包括Sonrotoclax、Tarlatamab、Zanidatamab、Blinatumomab、BGB-26808、BGB-R046、BG-68501、BG-C9074、BGB-43395、Xaluritamig等。
发行价格：
--
{"stockData":{"symbol":"06160","market":"HK","secType":"STK","nameCN":"百济神州","latestPrice":196.1,"timestamp":1785398902006,"preClose":199.1,"halted":0,"volume":3592955,"delay":0,"changeRate":-0.015067805123053743,"floatShares":1426000000,"shares":1541000000,"eps":1.4903480354859713,"marketStatus":"已收盘","change":-3,"latestTime":"07-30 16:08:22","open":201.6,"high":202.6,"low":193.3,"amount":705629741,"amplitude":0.04671,"askPrice":196.2,"askSize":10700,"bidPrice":196.1,"bidSize":2300,"shortable":3,"etf":0,"ttmEps":2.657353298767718,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785461400000},"marketStatusCode":5,"adr":0,"listingDate":1533657600000,"exchange":"SEHK","adjPreClose":199.1,"openAndCloseTimeList":[[1785375000000,1785384000000],[1785387600000,1785398400000]],"volumeRatio":1.022501,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"BOM.HK","astockBrief":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"百济神州","latestPrice":259.51,"timestamp":1785394800000,"preClose":268.6,"halted":0,"volume":4372100,"delay":0,"premium":"-34.96"},"impliedVol":0.3785,"impliedVolPercentile":0.155},"requestUrl":"/m/hq/s/06160","defaultTab":"news","newsList":[{"id":"2655769018","title":"百济神州拟发行86.6万股新股 用于落实2018员工购股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2655769018","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655769018?lang=zh_cn&edition=full","pubTime":"2026-07-30 18:41","pubTimestamp":1785408060,"startTime":"0","endTime":"0","summary":"7月30日，百济神州（688235/06160/BGNE）发布公告，公司拟向全资附属公司BGNC2发行86.6万股新股用于2018员工购股计划，股份后续将交付合格雇员，实际交付数量或低于发行规模。本次发行在股东大会授权限额内推进，当前计划参与者约4694名。新股份将用于履行2018员工购股计划相关股份交付义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607303826854051.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607303826854051.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2328871848.SGD","KURE","LU1719994722.HKD","688235","BK1500","LU0307460666.USD","LU1969619763.USD","BK1583","LU1251922891.USD","BK4585","LU0588546209.SGD","LU1770034418.SGD","BK0239","BK4526","06160","BK4588","BK1588","BK1161","ONC","LU1303224171.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128742735","title":"百济神州(06160)拟向全资子公司配发86.61万股新股以履行员购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1128742735","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128742735?lang=zh_cn&edition=full","pubTime":"2026-07-30 18:06","pubTimestamp":1785405983,"startTime":"0","endTime":"0","summary":"百济神州有限公司7月30日公告称，公司董事会已根据股东特别大会及瑞士章程第4a条授权，拟通过向其全资附属公司BGNC2配发及发行866,073股每股面值0.0001美元的新股份，以满足2018员工购股计划当前认购期的交付需求。发行完成后，百济神州注册股本将由154,097.5898美元增至154,184.1971美元；股份总数由1,540,975,898股增至1,541,841,971股。百济神州表示，此次向BGNC2配股将简化向员工交付股份的行政流程并提升效率。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655783588","title":"百济神州(06160)根据股份计划发行86.61万股新股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2655783588","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655783588?lang=zh_cn&edition=full","pubTime":"2026-07-30 18:02","pubTimestamp":1785405732,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，根据公司股东于股东特别大会批准的瑞士章程第4a条所规定的股本区间内增加或减少股本的授权，公司将通过向BGNC2(公司的一间全资附属公司)发行86.61万股新股份的方式增加其股本。经发行，新股份将转让予公司并为2018员工购股计划项下参与者的利益持有，以在当前认购期结束时向该等参与者交付其所购股份数目。实际交付予参与者的新股份数目将基于当前认购期结束时所购股份数目确定，该数目可能少于86.61万股新股份。股份发行将依据公司股东于2026年6月11日举行之股东周年大会批准的计划授权限额作出。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU0307460666.USD","LU0588546209.SGD","BK4585","LU1969619763.USD","LU1719994722.HKD","BK1500","BK1588","KURE","LU2328871848.SGD","BK4139","LU1770034418.SGD","BK1583","LU1251922891.USD","LU1303224171.USD","ONC","06160","BK4526","BK0239","688235","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190780676","title":"财报前瞻｜百济神州本季度营收预计增速稳健，机构观点偏正面","url":"https://stock-news.laohu8.com/highlight/detail?id=1190780676","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190780676?lang=zh_cn&edition=full","pubTime":"2026-07-29 23:58","pubTimestamp":1785340696,"startTime":"0","endTime":"0","summary":"百济神州将于2026年08月05日发布最新季度财报，市场关注盈利修复与核心品种放量节奏。市场一致预期显示，本季度百济神州营收预计为15.91亿美元，同比增长数据未明确；预计毛利率未披露；预计净利润或净利率未披露；预计调整后每股收益为0.15美元，同比增幅为146.88%。发展前景最大的现有业务来自“医药产品”，上季度实现收入15.13亿美元，同比增长32.84%。综合近期机构观点，偏正面的比例占优。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜百济神州本季度营收预计增速稳健，机构观点偏正面","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121773889","title":"异动解读｜百济神州盘中上涨3.33%，野村上调目标价至270.74港元提振情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1121773889","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121773889?lang=zh_cn&edition=full","pubTime":"2026-07-29 09:32","pubTimestamp":1785288752,"startTime":"0","endTime":"0","summary":"7月29日，百济神州盘中上涨3.33%，报200.6港元，成交额4543.82万港元，扭转前一交易日跌逾3%的弱势。消息面上，野村近日发布研报，上调百济神州目标价至270.74港元，预测公司次季经营利润同比增长74%。此前华福证券亦首次覆盖给予\"买入\"评级，目标价297.44港元，认为公司已迈入多曲线增长新纪元。此外，公司近期宣布追加投资3亿美元扩建美国生产基地和临床研发中心，叠加百悦泽MANGROVE 3期临床达到主要终点等积极进展，基本面催化持续释放。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百济神州盘中上涨3.33%，野村上调目标价至270.74港元提振情绪","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655832949","title":"港股开盘向好 恒指高开0.7% 理想汽车-W（02015）涨4.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655832949","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655832949?lang=zh_cn&edition=full","pubTime":"2026-07-29 09:25","pubTimestamp":1785288345,"startTime":"0","endTime":"0","summary":"北京汽车高开2.33%，惟公司发盈警，预期将录得截至2026年6月30日止六个月归属于公司权益持有人的净亏损约为15.5亿元至16.5亿元人民币，较2025年同期出现由盈转亏的变动。该公司认为，由于2026年上半年国内汽车行业竞争激烈，该公司销量未达预期，叠加原材料上涨以及加大市场投入等因素影响，综合导致归属于公司权益持有人的净亏损。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/YjE5MTg4YjVmOWZlYmUxNDMyNzYzODgyMzAy.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjE5MTg4YjVmOWZlYmUxNDMyNzYzODgyMzAy.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986989","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345780950.USD","LU1366334651.USD","03033","LU0737861699.HKD","IE00B19Z5X02.USD","HK0000306701.USD","LU0588546209.SGD","LU1522347837.USD","LU0516423174.USD","LU1242518857.USD","IE00B031J352.USD","BK1521","LU3063872942.SGD","BK1528","LU0140636845.USD","02833","09088","LU0823426308.USD","LU0865486749.SGD","LU0572944931.SGD","LU0856984785.SGD","LU1242518931.SGD","SG9999004220.SGD","BK1141","LU0348783233.USD","LU2242644610.SGD","LU0979878070.USD","SG9999002562.SGD","LU0516423091.SGD","LU0181495838.USD","LU0640798160.USD","83115","02800","LU1115378108.SGD","LU1303224171.USD","BK1604","IE0032431581.USD","LU2097828474.EUR","LU0588545730.USD","00992","LU0819121731.USD","LU2328871848.SGD","LU0650527681.SGD","HK0001040143.USD","LU1328277881.USD","LU1831875114.USD","LU1813983027.USD","LU2187417386.USD","BK1502","LU2929501877.USD","LU0327786744.USD","LU0417516902.SGD","LU0708995583.HKD","07226","LU0251144936.SGD","02057","BK1212","BK1237","LU0348735423.USD","LU0572940350.SGD","LU0821914370.USD","LU1102505762.USD","LU0359202008.SGD","LU0310800965.SGD","LU2125910500.SGD","BK1583","IE0008369823.USD","SG9999001093.SGD","BK1233","01378","BK1526","LU0315179316.USD","LU0456846285.SGD","IE00BGHQDM52.EUR","LU1051768304.USD","LU0441854154.USD","LU0048597586.USD","IE0031814852.USD","LU0828237940.HKD","LU0359201612.USD","BK1541","LU0072462343.USD","IE00BVYPNP33.GBP","LNVGY","LU0607220059.USD","LU1235295612.USD","LU1634259391.SGD","LU2097828714.EUR","01958","03417","02269","LU0315178854.USD","LU0307460666.USD","06862","BK1172","TCHI","LU0972618739.USD","82800","KURE","LU1251922891.USD","LU1211504680.USD","LU1366334578.USD","LU0630314457.HKD","06160","LU1188198961.HKD","HSI","LU0128522157.USD","LU0561508036.HKD","LU0516422440.USD","LU0588545904.SGD","00857","09858","LU0456827905.SGD","LU0572939691.SGD","BK1226","02313","IE0003895053.USD","LU1224709979.USD","LU1282651048.USD","LU1770034418.SGD","LU0675040207.SGD","SGXZ62798434.SGD","MCHmain","IE00B031HY20.USD","LU0293314216.USD","07200","BK1588","LU0173614495.USD","LU0244354667.USD","LU0320764599.SGD","03088","IE00BVYPNQ40.USD","LU1720050803.USD","IE0008368742.USD","HHImain","BK1575","07500","LU0634319403.HKD","LU0228367735.SGD","LU0672654166.SGD","LU1048596156.SGD","LU1224444064.USD","LU1634259557.SGD","LU1785774172.SGD","LU0417516738.SGD","LU0405327494.USD","BK1594","LU1880383366.USD","LU0043850808.USD","LU0605514214.HKD","LU1969619763.USD","BK1587","LU0039217434.USD","09115","LU0128525689.USD","07552","LU0348805143.USD","80992","LU0405327148.USD","03419","02837","IE00BQJZWZ67.USD","IE00BWDBJ730.SGD","LU0052750758.USD","ZTO","BK1500","IE00BPRC5H50.USD","LU0594300419.USD","02015","LU0345781412.USD","BK1592","LU0543330483.HKD","LU0823426480.USD","BK1591","LU0287142896.SGD","BK1227","513600","601857","LU0163747925.USD","BK1539","LU0463099449.HKD","LU0862451837.USD","LU2399975544.HKD","IE00BZ08YT58.USD","LU2293587155.HKD","LI","LU0051755006.USD","LU0348783662.USD","LU1515016050.SGD","LU0651946864.USD","BK1589","HK0000306685.HKD","LU1046422090.SGD","03067","688235","HK0000320223.HKD","SGXZ86797644.SGD","LU0326950275.SGD","IE00B29SXG58.USD","LU2045819591.USD","LU1961090484.USD","LU1719994722.HKD","SG9999003461.SGD","LU0348827113.USD","07300","03423","03032","BK1161","HSTECH","IE00B5MMRT66.SGD","LU0264606111.USD","LU0314109678.HKD","LU0348825331.USD","LU0516422952.EUR","BK1151","BK1119","LU0052756011.USD","LU0611395673.USD","LU0149534421.HKD","LU1102505929.USD","LU0791590937.USD","LU2097828557.USD","WXXWY","HK0000320264.USD","BK1610","09067","LU0588545490.SGD","LU0890818403.SGD","LU1282651121.HKD","LU0791591158.USD","LU2097828631.EUR","LU1794554557.SGD","SG9999001226.SGD","LU0862451753.SGD","IE00BYV24P56.USD","LU1023057109.AUD","LU2097828805.USD","SG9999014674.SGD","IE00B543WZ88.USD","BK1175","BK1576","LU0049112450.USD","03115","LU0516422366.SGD","01928","LU1267930227.SGD","IE00BZ08YR35.GBP","LU0702159699.USD","LU2039709279.SGD","SG9999002463.SGD","LU0359201885.HKD","LU0029875118.USD","LU1166156734.SGD","SG9999006597.SGD","LU0211977185.USD","03037","LU1688375341.USD","IDRV","LU0320764755.SGD","IE00BZ08YS42.EUR","ONC","IE00BMCWC346.EUR","SCHYY","LU1497733631.SGD","LU1497734951.SGD","LU2488822045.USD","LU1048588211.SGD","LU1497733557.USD","LU0594300179.USD","LU0348784397.USD","BK1607","LU1675838814.USD","LU0469268626.HKD","LU0540923850.HKD","LU1808992512.USD","LU2351347302.SGD","HK0001040168.HKD","LU0417516571.SGD","IE0034224299.USD","IE00B0JY6N72.USD","BK1193"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655832649","title":"【券商聚焦】国泰海通证券：全球多肽CDMO进入产能扩张周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2655832649","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655832649?lang=zh_cn&edition=full","pubTime":"2026-07-29 09:21","pubTimestamp":1785288070,"startTime":"0","endTime":"0","summary":"国内外的多肽CDMO公司均加大对于产能的投资建设，尤其注重从临床前到商业化生产的一站式服务能力建设。2026年4月，凯莱英医药与天津经开区管委会签署合作备忘录，在天津经开区持续扩建化学大分子创新药CDMO研发生产基地，预计投资规模达20亿元人民币。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986985","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","LU0359202008.SGD","IE00B5MMRT66.SGD","06185","BK1141","LU0588546209.SGD","601211","LU1719994722.HKD","02611","02142","KURE","LU2476274308.USD","06160","02616","161027","IE00B543WZ88.USD","LU0052750758.USD","LU0181495838.USD","BK1583","LU0417516738.SGD","LU0348784397.USD","BK1588","09926","LU0634319403.HKD","IE00B0JY6N72.USD","SG9999002463.SGD","09688","LU2242644610.SGD","LU1720050803.USD","BK1147","09995","HK0000165453.HKD","LU0307460666.USD","LU0561508036.HKD","01093","01877","KCE","LU0051755006.USD","02269","LU1251922891.USD","LU1328277881.USD","01177","BK1564","01801","BK1610","LU0067412154.USD","LU1008478684.HKD","LU0979878070.USD","CDMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198677871","title":"异动解读｜百济神州盘中下跌3.15%，生物科技板块集体回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1198677871","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198677871?lang=zh_cn&edition=full","pubTime":"2026-07-28 14:34","pubTimestamp":1785220444,"startTime":"0","endTime":"0","summary":"7月28日，百济神州盘中下跌3.15%，报193.5港元，成交额4.37亿港元。生物科技板块整体承压，所属行业个股普遍走低，维立志博-B跌8.35%，康诺亚-B跌5.22%，康方生物跌3.55%，三生制药跌1.4%。消息面上，近一个月恒生医疗保健指数此前累计上涨17.4%，跑赢大市，短期获利盘回吐压力加大。此外，公司此前披露境内子公司需补缴税款及滞纳金约4.46亿元，将计入当期损益，对短期利润构成一定压制。公司将于8月5日发布二季度业绩，中报季临近叠加前期涨幅较大，资金获利了结情绪升温。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"百济神州盘中下跌3.15%，生物科技板块集体回调","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654458022","title":"【券商聚焦】交银国际：下半年医药板块有望迎来修复 但内部分化或持续加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2654458022","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654458022?lang=zh_cn&edition=full","pubTime":"2026-07-28 10:01","pubTimestamp":1785204072,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，近一个月恒生医疗保健指数涨17.4%，跑赢大市。其中，生物药、CXO及处方药板块表现较优于其他板块。机构持仓方面，2026年年中以来，内资持仓延续提升态势，而外资则略有降低。该机构指，中报季临近，7月以来多家公司业绩预告陆续发布，CXO板块表现亮眼，业绩和订单延续高增长态势。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986903","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093","LU0196878994.USD","LU2399975544.HKD","01548","01801","02162","02269","LU1720050803.USD","BK1521","HK0000320223.HKD","LU0588546209.SGD","LU1813983027.USD","06996","09926","LU2097828714.EUR","03329","LU2328871848.SGD","159938","LU2476274308.USD","01276","02268","BK1219","06821","LU1880383366.USD","LU0348783233.USD","LU0856984785.SGD","HK0000165453.HKD","09996","00013","BK1587","02273","03759","02596","03692","06078","01952","06160","LU0634319403.HKD","KCE","09966","01951","01177","09939","01530","LU0417516571.SGD","02096","LU2039709279.SGD","06990","KURE","LU0572944931.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654209775","title":"大行评级丨野村：上调百济神州目标价至270.74港元，预测次季经营利润同比增74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654209775","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654209775?lang=zh_cn&edition=full","pubTime":"2026-07-27 15:22","pubTimestamp":1785136927,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4588","KURE","BK4585","LU1719994722.HKD","LU2328871848.SGD","BK1588","LU0307460666.USD","ONC","LU1770034418.SGD","EWH","06160","LU1303224171.USD","BK1500","BK0239","BK1583","LU1969619763.USD","BK4526","688235","LU1251922891.USD","BK1161","LU0588546209.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654252095","title":"每日科创｜百济神州（688235）：25年首度盈利，稳居科创板市值最高药企","url":"https://stock-news.laohu8.com/highlight/detail?id=2654252095","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654252095?lang=zh_cn&edition=full","pubTime":"2026-07-27 10:34","pubTimestamp":1785119677,"startTime":"0","endTime":"0","summary":"2026年4月14日，百济神州交出了一份具有里程碑意义的成绩单：全年营收382.25亿元，同比增长40.46%；归母净利润14.61亿元，而上年同期为亏损49.78亿元——这是公司自2010年成立以来首次实现年度盈利。2025年，公司研发费用达155.08亿元，同比增长9.67%，再创历史新高。自2021年登陆科创板以来，百济神州累计研发投入已超过630亿元。截至2026年7月，据Wind一致预期，15家机构对百济神州2026年业绩作出预测，一致预期净利润为45.72亿元，同比增长213%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026072700006940.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU2328871848.SGD","159982","BK1583","KURE","LU0307460666.USD","LU0588546209.SGD","LU1303224171.USD","LU1251922891.USD","BK1161","BK1588","LU1969619763.USD","06160","LU1770034418.SGD","BK1500","LU1719994722.HKD","688235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653701077","title":"百济神州(06160)涨3.92% 拟追加投资3亿美元扩建美国生产基地和临床研发中心","url":"https://stock-news.laohu8.com/highlight/detail?id=2653701077","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653701077?lang=zh_cn&edition=full","pubTime":"2026-07-24 09:59","pubTimestamp":1784858358,"startTime":"0","endTime":"0","summary":"金吾财讯 | 百济神州 日内震荡走高，盘中最高触及202.400港元，最新为201.400港元，涨幅3.92%，成交额1.71亿港元。消息面上，7月23日，百济神州宣布将追加投资3亿美元，扩建位于美国新泽西州霍普韦尔普林斯顿西部创新园区的旗舰生产基地和临床研发中心，新增小分子药物生产能力，完善公司全球化生产和供应体系。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986671","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688235","BK1161","ONC","BK4588","KURE","BK1500","BK0239","LU1969619763.USD","LU1770034418.SGD","LU1303224171.USD","LU0307460666.USD","BK4139","BK4526","06160","BK1588","BK1583","LU2328871848.SGD","LU1251922891.USD","BK4585","LU1719994722.HKD","LU0588546209.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197960455","title":"异动解读｜百济神州盘中上涨4.13%，追加3亿美元扩大美国生产布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1197960455","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197960455?lang=zh_cn&edition=full","pubTime":"2026-07-24 09:48","pubTimestamp":1784857735,"startTime":"0","endTime":"0","summary":"7月24日，百济神州盘中上涨4.13%，报201.0港元/股，成交额1.62亿港元。消息面上，公司于7月23日宣布追加3亿美元投资扩大美国生产布局，进一步强化全球商业化产能。此外，公司核心产品泽布替尼（百悦泽）近期在套细胞淋巴瘤一线治疗3期临床研究MANGROVE中达到主要终点，使疾病进展或死亡风险降低43%，计划下半年进行全球注册申报。公司将于8月5日召开第二季度业绩电话会议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653074709","title":"百济神州/安进 FIC 双抗，皮下制剂进入 III 期","url":"https://stock-news.laohu8.com/highlight/detail?id=2653074709","media":"新浪医药","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653074709?lang=zh_cn&edition=full","pubTime":"2026-07-23 19:30","pubTimestamp":1784806200,"startTime":"0","endTime":"0","summary":"7 月 22 日，药物临床试验登记与信息公示平台显示，安进和百济神州共同登记了一项在接受含铂一线化疗后的复发性广泛期小细胞肺癌试验参与者中比较 Tarlatamab皮下给药与静脉给药的 III 期研究DeLLphi-315。在皮下剂型的开发方面，安进和百济神州于 2024 年 9 月启动了一项在广泛期小细胞肺癌受试者中评价 Tarlatamab 皮下给药的安全性、耐受性、药代动力学和初步抗肿瘤活性的 Ib 期研究 DeLLphi-308。而本次启动的DeLLphi-315 研究是塔拉妥单抗皮下给药方案启动的首个 III 期临床试验。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-07-23/doc-iniivazc5268721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688235","BK4139","BK4585","BK4588","LU0889565916.HKD","LU1969619763.USD","IE00B4R5TH58.HKD","LU2328871848.SGD","LU1251922891.USD","BK4534","LU2468319806.SGD","BK1500","ONC","IE00BFTCPJ56.SGD","LU1719994722.HKD","LU1770034418.SGD","SG9999001440.SGD","PBE","LU2242646821.SGD","LU1303224171.USD","LU0289739699.SGD","IBB","LU0058720904.USD","BK1583","IBBQ","PJP","LU2242652126.USD","LU0588546209.SGD","III","BK4599","LU0307460666.USD","LU2112291526.USD","BIB","LU1061106388.HKD","LU0122379950.USD","BK4134","LU0868494617.USD","06160","BK1588","BBH","BK4581","KURE","LU0320765992.SGD","IE0002141913.USD","LU1571399168.USD","TBXU","IE00BJT1NW94.SGD","AMGN","IE0009355771.USD","LU1983299246.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653490457","title":"百济神州追加3亿美元投资扩大美国生产布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2653490457","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653490457?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:45","pubTimestamp":1784803543,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1251922891.USD","KURE","06160","LU0307460666.USD","LU1303224171.USD","LU0588546209.SGD","LU1719994722.HKD","BK0239","BK1161","BK1588","LU1969619763.USD","LU2328871848.SGD","LU1770034418.SGD","BK1583","688235","BK1500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653715567","title":"百济神州汪来：公司的背水一战，研发做了这些事","url":"https://stock-news.laohu8.com/highlight/detail?id=2653715567","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653715567?lang=zh_cn&edition=full","pubTime":"2026-07-23 12:05","pubTimestamp":1784779520,"startTime":"0","endTime":"0","summary":"从2010年成立至今，百济神州（ONC.US、06160.HK、688235.SH）已成为A股市值最高的药企，这背后离不开旗下一款重磅药物BTK抑制剂泽布替尼的开发成功，这也是公司当前的“利润奶牛”来源。7月22日，在首届大国新药全球会议（CPIC2026）上，百济神州总裁、全球研发负责人汪来回顾了公司如何背水一战投入换来泽布替尼成功故事。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607233818666284.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607233818666284.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06160","BK4139","LU1303224171.USD","BK1500","ONC","BK0239","BK4585","LU0307460666.USD","LU1770034418.SGD","LU0588546209.SGD","LU2328871848.SGD","KURE","BK1583","LU1969619763.USD","BK1588","688235","BK1161","LU1719994722.HKD","LU1251922891.USD","BK4588","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653220610","title":"7月21日百济神州涨6.25%，创新药ETF银华基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653220610","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653220610?lang=zh_cn&edition=full","pubTime":"2026-07-21 16:35","pubTimestamp":1784622941,"startTime":"0","endTime":"0","summary":"证券之星消息，7月21日百济神州涨6.25%，收盘报275.5元，换手率6.82%，成交量7.84万手，成交额20.67亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共31家，其中持有数量最多的公募基金为银华基金的创新药ETF银华。创新药ETF银华目前规模为159.65亿元，最新净值0.871，较上一交易日上涨3.41%，近一年下跌0.9%。创新药ETF银华的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100030524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","KURE","LU1969619763.USD","688235","LU1251922891.USD","LU1719994722.HKD","06160","BK1161","BK1588","LU0588546209.SGD","LU1303224171.USD","159316","LU2328871848.SGD","LU0307460666.USD","BK1500","LU1770034418.SGD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653693220","title":"百济神州涨6.25%，中邮证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2653693220","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653693220?lang=zh_cn&edition=full","pubTime":"2026-07-21 16:35","pubTimestamp":1784622932,"startTime":"0","endTime":"0","summary":"今日百济神州涨6.25%，收盘报275.5元。2026年5月13日，中邮证券研究员盛丽华,陈灿发布了对百济神州的研报《泽布替尼同比维持高增，全年业绩指引上调》，该研报对百济神州给出“买入”评级。公司为创新药出海龙头企业，全球商业化能力突出、在研管线即将进入收获期，维持“买入”评级。百济神州个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100030521.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688235","06160","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652269822","title":"创新药板块活跃 荣昌生物(09995)涨7.28% 多支头部公募大举举牌港股创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2652269822","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652269822?lang=zh_cn&edition=full","pubTime":"2026-07-20 10:26","pubTimestamp":1784514372,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药板块活跃，荣昌生物 涨7.28%，歌礼制药-B涨6.81%，科伦博泰生物涨6.70%，康诺亚-B涨6.25%，康方生物涨5.83%，药明合联涨5.53%，石药集团涨4.94%，三生制药涨5.02%，信达生物涨4.55%，药明生物涨4.60%，恒瑞医药涨4.00%，百济神州涨3.88%。头部机构密集触及举牌线，凸显对创新药板块的看好。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986240","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348827113.USD","06978","SG9999002463.SGD","IE00BZ08YT58.USD","BK1588","KCAI","LU0516423174.USD","LU1242518931.SGD","01530","LU0979878070.USD","IBBQ","01672","BK1593","159992","LU2399975544.HKD","HK0000165453.HKD","688331","LU0516422440.USD","LU0708995583.HKD","BK0239","LU1720050803.USD","LU0327786744.USD","LU2097828474.EUR","01093","LU0359201612.USD","LU0196878994.USD","06990","LU0043850808.USD","LU2328871848.SGD","LU1242518857.USD","02269","02162","LU0417516738.SGD","VXUS","09926","LU1064130708.USD","06160","BK1576","LU1226288170.HKD","LU1951186391.HKD","LU0348735423.USD","BK4585","01801","MEDX","KURE","LU0052750758.USD","LU0516422366.SGD","09995","02268","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163693864","title":"异动解读｜百济神州盘中上涨3.39%，报192.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1163693864","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163693864?lang=zh_cn&edition=full","pubTime":"2026-07-20 09:52","pubTimestamp":1784512342,"startTime":"0","endTime":"0","summary":"7月20日，百济神州盘中上涨3.39%，报192.5港元/股，成交额1.94亿港元。百济神州所在的生物科技行业中，个股普遍走强，其中荣昌生物涨6.62%，科伦博泰生物涨5.57%，信达生物涨4.1%，康方生物涨3.45%，三生制药涨3.34%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beonemedicines.com","stockEarnings":[{"period":"1week","weight":0.0132},{"period":"1month","weight":0.141},{"period":"3month","weight":0.1469},{"period":"6month","weight":-0.0363},{"period":"1year","weight":0.071},{"period":"ytd","weight":0.1104}],"compareEarnings":[{"period":"1week","weight":0.0368},{"period":"1month","weight":0.1208},{"period":"3month","weight":0.0012},{"period":"6month","weight":-0.0577},{"period":"1year","weight":0.0111},{"period":"ytd","weight":0.0069}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"BeOne Medicines AG（原名：BeiGene Ltd）是一家全球肿瘤学公司，致力于为全球癌症患者研发新疗法。该公司产品组合涵盖血液学和实体瘤，致力于开发多样化的新型疗法。其产品包Brukinsa、Tevimbra和Pamiparib。Brukinsa是一种口服的布鲁顿酪氨酸激酶(BTK)小分子抑制剂。Tevimbra是一种人源化免疫球蛋白G4（IgG4）抗程序性细胞死亡蛋白1（PD-1）单克隆抗体，具有高亲和力和对PD-1的结合特异性。Tevimbra旨在最大限度地减少与巨噬细胞上Fc-γ（Fcy）受体的结合，帮助人体免疫细胞检测和对抗肿瘤。该公司正在开发的产品线包括Sonrotoclax、Tarlatamab、Zanidatamab、Blinatumomab、BGB-26808、BGB-R046、BG-68501、BG-C9074、BGB-43395、Xaluritamig等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.027621},{"month":2,"riseRate":0.5,"avgChangeRate":0.032126},{"month":3,"riseRate":0.125,"avgChangeRate":-0.059409},{"month":4,"riseRate":0.5,"avgChangeRate":0.034277},{"month":5,"riseRate":0.375,"avgChangeRate":-0.043816},{"month":6,"riseRate":0.375,"avgChangeRate":0.001624},{"month":7,"riseRate":0.875,"avgChangeRate":0.106023},{"month":8,"riseRate":0.857143,"avgChangeRate":0.058603},{"month":9,"riseRate":0.5,"avgChangeRate":0.025162},{"month":10,"riseRate":0.5,"avgChangeRate":-0.027038},{"month":11,"riseRate":0.625,"avgChangeRate":0.118183},{"month":12,"riseRate":0.125,"avgChangeRate":-0.07577}],"exchange":"SEHK","name":"百济神州","nameEN":"BEIGENE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(06160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,06160,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(06160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}